Skeletal Muscle Modulates Huntington's Disease Pathogenesis in Mice: Role of Physical Exercise by Blanco, Gonzalo et al.
This is a repository copy of Skeletal Muscle Modulates Huntington's Disease 
Pathogenesis in Mice: Role of Physical Exercise.




Blanco, Gonzalo orcid.org/0000-0003-3827-3111, Corrochano, Silvia and Acevedo-
Arozena, Abraham (2018) Skeletal Muscle Modulates Huntington's Disease Pathogenesis 






This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License  
(http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission 
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
https://doi.org/10.1177/1179069518809059
Journal of Experimental Neuroscience 
Volume 12: 1–3
© The Author(s) 2018
DOI: 10.1177/1 7906951880905
It is undeniable that physical exercise can improve health. 
However, we and others have shown that at least in some situ-
ations, such as in disorders that can lead to alterations in skel-
etal muscle metabolism, including Huntington’s disease (HD), 
certain types of exercise can accelerate disease onset and 
progression.
In most neurodegenerative disorders, the brain is not the 
only affected part of the body, and systemic alterations are evi-
dent. This is not surprising, as many of the genes identified as 
causative of neurodegeneration (eg, the pathological expan-
sions in the first exon of the huntingtin gene responsible for 
HD) are ubiquitously expressed. In particular, disorders that 
lead to motor impairments, such as HD and amyotrophic lat-
eral sclerosis (ALS), have prominent systemic alterations. In 
HD patients and mouse models, the disease seems to increase 
energy consumption and demands, leading to a hypermetabolic 
state.1 As the energy resources are depleted, muscle wasting 
and weight loss become indicators of disease progression. 
Skeletal muscle plays a key role in the regulation of whole-
body metabolism, glycaemia, and energy balance. As promi-
nent muscle dysfunction occurs in HD and other 
neurodegenerative disorders, these systemic alterations are 
likely to be mediated, at least in part, by dynamic changes in 
skeletal muscle function through the progression of the neuro-
degenerative process. These metabolic changes are manifested 
in skeletal muscle by a switch of muscle fibres towards more 
oxidative types, typically from type II to type I fibres (glycolytic 
to oxidative type), accompanied by changes in mitochondrial 
bioenergetics and biogenesis.
In HD, Parkinson’s disease (PD), ALS, and other neurode-
generative movement disorders, mitochondrial biogenesis and 
functions are compromised. In particular, lower levels and 
activity of PGC-1α (peroxisome proliferator–activated recep-
tor-gamma co-activator 1 alpha) have been reported in cellular 
and animal models and in patients of ALS, PD, and HD.2–4 
It is then not surprising that increasing mitochondrial function 
is being pursued as a promising therapeutic approach in these 
neurodegenerative disorders. There is some evidence in the lit-
erature suggesting that increasing mitochondrial biogenesis 
could be beneficial for HD pathogenesis, for example, by over-
expressing PGC-1α at the neuronal level in the striatum (and 
in cellular models).5,6 However, these possible beneficial effects 
may not be generalised to other neurodegenerative conditions. 
In ALS, overexpression of PGC-1α in skeletal muscle of a 
mouse model increased mitochondrial biogenesis and muscle 
function without affecting disease progression, or extending 
survival,7 whereas general overexpression of PGC-1α seems to 
delay the progression of the disease in a mouse model of ALS.8 
In Alzheimer’s disease (AD), overexpression of PGC-1α in a 
mouse model was detrimental for the disease through a mecha-
nism involving impairing autophagy leading to the accumula-
tion of toxic amyloid beta (AB).9
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In our recent study using HD mouse models,10 we have 
shown that systemic HD pathogenesis can be modulated by 
local alterations in skeletal muscle that in turn can affect 
whole-body metabolism. Through an unbiased mutagenesis 
approach to find new HD modifier genes, we found that muta-
tions in Scn4a act as potent enhancers of HD pathogenesis in 
the mouse. Scn4a, the gene encoding the skeletal muscle–spe-
cific voltage-gated sodium channel (Nav1.4), is expressed at 
high levels only in skeletal muscle, whereas the transcript is 
barely detectable in the brain. This unique pattern of expres-
sion allowed us to conclude that the systemic modifier effects 
were primarily mediated by local changes in HD pathology in 
skeletal muscle. Overall, the genetic interaction of both muta-
tions (HD and Scn4a) led to the exacerbation of the systemic 
hypermetabolic state of HD mice, making the mice leaner than 
HD controls from an early age. This was accompanied by a 
depletion of energy sources from blood, including lower circu-
lating glucose and fatty acid levels in double mutants. Enlarged 
mitochondria appeared in skeletal muscle of HD mice carrying 
Scn4a mutations, coupled with an almost complete switch 
towards more oxidative fibre types. Crucially, at least ex vivo, 
these enlarged mitochondria from the double mutant mice 
were functional, as when purified they were able to produce 
more energy than those from their HD littermate controls. All 
these changes were underlined by the activation of AMP-
activated protein kinase (AMPK) in skeletal muscle, coupled 
with an increase in huntingtin accumulation in skeletal muscle. 
Altogether, our results suggest that increasing mitochondrial 
biogenesis and function in skeletal muscle causes further per-
turbations of the fragile energetic status of HD mice and can 
lead to deleterious effects on overall HD pathogenesis.
Intriguingly, one of the main adaptations observed in skel-
etal muscles of individuals that routinely perform endurance 
exercise training is an increase in mitochondrial biogenesis and 
bioenergetics remodelling. These adaptations are orchestrated 
by the activity of major regulators, such as AMPK and PGC-
1α, and are coupled with fibre-type switching. Thus, endurance 
exercise can lead to similar adaptations in healthy individuals 
than those observed in the HD; Scn4a double mutant mice. 
This observation prompted us to consider that endurance 
training leading to AMPK activation in skeletal muscle could 
also be detrimental for HD.
The effects of physical exercise as a possible therapeutic 
intervention for HD have led to disparaging results. In 
patients, a recent clinical trial of moderate exercise concluded 
that it was not detrimental for the disease, although more evi-
dence was needed to assess its possible beneficial effects.11 In 
our study, the effects of endurance exercise were also deleteri-
ous for HD pathogenesis. Indeed, different types of exercise 
routines might exert some beneficial effects on the neurode-
generative process, especially at presymptomatic stages. In 
particular, aerobic exercise leads to benefits on clinically 
depressed patients, which is one of the clinical manifestations 
of HD and other neurodegenerative disorders. Moreover, 
exercise has been shown to improve cognition through the 
induction of neurotrophic factors such as brain-derived neuro-
trophic factor (BDNF) and can induce adult hippocampal 
neurogenesis.12 However, in previous studies using HD mouse 
models, moderate exercise regimes have not led to any changes 
in the overall disease onset or progression, despite inducing 
neurogenesis in the hippocampus.13 Thus, it seems that the 
beneficial effects of exercise are more evident at the cognitive 
level and increasing neurogenesis, whereas the effects of exer-
cise on overall disease progression remain unclear. Hence, a 
consistent picture of the effects of physical exercise in different 
models of neurodegenerative disorders has not yet emerged.
Moreover, mimicking endurance training with pharmaco-
logic compounds in mouse models of HD did not result in 
locomotor or survival improvement. AICAR is a drug that 
stimulates the activation of AMPK and is therefore considered 
to behave as an exercise mimetics drug. AICAR injections in 
HD mice led to improved cognition and coordination without 
extending survival in one study, but to increase apoptosis and 
accelerated death in another.14 Moreover, AMPK activation 
and nuclear translocation in the brain can lead to detrimental 
effects in HD,15 supporting the idea that stimulating mitochon-
drial biogenesis and the bioenergetics of the cells that are under 
a critical diseased situation, such as the alterations induced by 
mutant huntingtin, might not be the most optimal therapeutic 
option for this disorder. An explanation for the possible detri-
mental effects of increasing mitochondrial biogenesis in HD 
could be that although mitochondria seem functional in the 
HD context, they could also be damaged by the effects of 
mutant huntingtin, leading to the production of more oxidative 
stress and damage that could accumulate over time. Indeed, 
AMPK activation should lead to the activation of autophagy 
and mitophagy, but this effect is likely compromised in the HD 
context, as we implied by the accumulation of mutant hunting-
tin, LC3-II, and the appearance of altered mitochondria in 
double mutant HD; Scn4a skeletal muscles.10 Therefore, the 
possible benefits of incrementing mitochondrial function in 
HD pathogenesis may be observed only when they are accom-
panied by a continuous supply of energy in an environment 
where those mitochondria might not be damaged by the pres-
ence of mutant huntingtin.
In summary, increasing energy demands in skeletal muscle 
through genetic means or by an endurance physical exercise 
regime, at least in the mouse, are detrimental for HD patho-
genesis. This highlights the key role of the periphery in modu-
lating a neurodegenerative disorder like HD. Alterations in 
skeletal muscle metabolism can have a great impact on sys-
temic metabolism, leading to pleotropic effects observed in the 
disease. An intriguing possibility is that skeletal muscle dys-
function in HD could lead to changes in the secretion pattern 
of myokines that mediate the beneficial effects of physical exer-
cise from skeletal muscle to the brain. Clearly, more research is 
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needed to further understand the effects that skeletal muscle 
dysfunction may have on HD and other neurodegenerative 
disorders, as well as the effects of physical exercise as a possible 
therapeutic intervention.
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